St. Louis encephalitis epidemiology and demographics

Jump to navigation Jump to search

St. Louis encephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating St. Louis encephalitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

St. Louis encephalitis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of St. Louis encephalitis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on St. Louis encephalitis epidemiology and demographics

CDC on St. Louis encephalitis epidemiology and demographics

St. Louis encephalitis epidemiology and demographics in the news

Blogs on St. Louis encephalitis epidemiology and demographics

Directions to Hospitals Treating St. Louis encephalitis

Risk calculators and risk factors for St. Louis encephalitis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Vishnu Vardhan Serla M.B.B.S. [2]

Overview

Epidemiology and Demographics

St. Louis encephalitis virus (SLEV) is transmitted to humans through the bite of an infected mosquito. All residents of and visitors to areas where SLEV activity has been identified are at risk of SLEV infection, particularly persons who engage in outdoor work and recreational activities, and those living in low-income areas. Most SLEV infections are silent; clinical infections range in severity from mild nonspecific febrile illnesses to meningitis or encephalitis. The risk of severe disease and fatality increases with age. SLEV infection is thought to confer life-long immunity against re-infection.

In the United States, the annual number of reported SLEV neuroinvasive disease cases reported fluctuates widely, as result of periodic epidemics. From 1964 through 2009, an average of 102 cases were reported annually (range 2-1,967). To ensure standardization of reporting across the country, CDC recommends that the national surveillance case definition be consistently applied by all state health departments.

In temperate areas of the United States, SLEV disease cases occur primarily in the late summer or early fall. In the southern states, where the climate is milder, cases can occur year round. Although the geographic range of the virus extends from Canada to Argentina, human cases have almost exclusively occurred in the United States. The majority of cases have occurred in eastern and central states, where episodic urban-centered outbreaks have recurred since the 1930s. In the rural west, transmission has followed a more endemic pattern. The largest epidemic of SLEV neuroinvasive disease ever recognized occurred in the United States in 1975, with nearly 2,000 cases reported, primarily from the central states in the Ohio-Mississippi River Basin.

References

Template:WH Template:WS